CheckEye is a cloud-based platform that utilizes machine learning algorithms to analyze photographic images of the eye fundus for the early detection of chronic diseases, including diabetic retinopathy. This technology enables non-medical staff to conduct screenings in various locations, significantly reducing waiting times and treatment costs while improving health outcomes for patients.
Funding
Funding not disclosed
Founders
Product
Problem
Chronic diseases, including diabetic retinopathy, are leading causes of death and blindness globally. Early diagnosis and treatment can prevent severe complications, but access to specialists and screening programs is often limited, leading to delayed intervention and increased healthcare costs.
Solution
CheckEye offers a cloud-based platform that uses AI algorithms to analyze images of the eye fundus for early detection of chronic diseases, including diabetic retinopathy. The platform enables non-medical personnel to conduct screenings in various locations, such as optical retailers and pharmacies. Images are uploaded to the system for automated analysis, providing quick and accurate results that facilitate timely treatment and reduce the burden on specialists. The AI-powered analysis achieves high accuracy, enabling early detection and prevention of vision loss.
Target Audience
The primary target audience includes public health systems, insurance companies, eye health professionals, and patients at risk of or affected by chronic diseases like diabetic retinopathy.
Features
- AI-driven analysis of eye fundus images for the detection of diabetic retinopathy and other chronic diseases
- Cloud-based platform accessible from various locations with minimal infrastructure requirements
- Screening can be performed by non-medical staff, expanding access to diagnostic services
- High diagnostic accuracy with 95% sensitivity and 90% specificity
- Automated image analysis reduces the need for manual grading and prioritizes patients for treatment
- Integration with the Ukrainian Diabetes Federation and participation in national screening programs
- Expansion to international markets, including partnerships with pharmacies and healthcare providers
- Capability to screen for over 40 chronic diseases, including neurodegenerative and cardiovascular conditions